Ute Hoch

3.7k total citations
86 papers, 2.1k citations indexed

About

Ute Hoch is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ute Hoch has authored 86 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 36 papers in Molecular Biology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ute Hoch's work include Cancer Immunotherapy and Biomarkers (21 papers), Cancer therapeutics and mechanisms (20 papers) and Cancer Treatment and Pharmacology (17 papers). Ute Hoch is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Cancer therapeutics and mechanisms (20 papers) and Cancer Treatment and Pharmacology (17 papers). Ute Hoch collaborates with scholars based in United States, United Kingdom and Belgium. Ute Hoch's co-authors include Paul R. Ortiz de Montellano, Peter Schreier, Chantu R. Saha‐Möller, Waldemar Adam, Michael A. Eldon, Judith A. Fox, Jonathan Zalevsky, Michael Lazarus, Mary Tagliaferri and Jeffrey A. Silverman and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Ute Hoch

86 papers receiving 2.0k citations

Peers

Countries citing papers authored by Ute Hoch

Since Specialization

Citations

This map shows the geographic impact of Ute Hoch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ute Hoch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ute Hoch more than expected).

Fields of papers citing papers by Ute Hoch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ute Hoch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ute Hoch. The network helps show where Ute Hoch may publish in the future.

Co-authorship network of co-authors of Ute Hoch

This figure shows the co-authorship network connecting the top 25 collaborators of Ute Hoch. A scholar is included among the top collaborators of Ute Hoch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ute Hoch. Ute Hoch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial 2023 ·Cancer Immunology Immunotherapy ·(unknown), Amy K. Erbe, Jennifer Birstler, KyungMann Kim, Ute Hoch, Sue Currie, (unknown), Danni Yu, Arlene O. Siefker‐Radtke, Nizar M. Tannir, Sara M. Tolaney, Adi Diab, Paul M. Sondel	2
2	Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study 2022 ·Journal for ImmunoTherapy of Cancer ·Nizar M. Tannir, (unknown), Adi Diab, Mario Sznol, Mehmet Asım Bilen, Arjun Vasant Balar, Giovanni Grignani, Erika Puente-Poushnejad, (unknown), David Chien, Ute Hoch, (unknown), Danni Yu, Sue Currie, Mary Tagliaferri, Jonathan Zalevsky, Arlene O. Siefker‐Radtke, Michael E. Hurwitz	21
3	A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors 2019 ·Cancer Discovery ·Salah-Eddine Bentebibel, Michael E. Hurwitz, Chantale Bernatchez, Cara Haymaker, Courtney W. Hudgens, Harriet M. Kluger, Michael T. Tetzlaff, Mary Tagliaferri, Jonathan Zalevsky, Ute Hoch, Christie Fanton, Sandra Aung, Patrick Hwu, Brendan D. Curti, Nizar M. Tannir, Mario Sznol, Adi Diab	169
4	Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol 2018 ·Clinical Cancer Research ·Hope S. Rugo, Javier Cortés, Ahmad Awada, Joyce O’Shaughnessy, Chris Twelves, Seock‐Ah Im, Alison L. Hannah, Lin Lü, Sherwin K. B. Sy, (unknown), Deborah A. Zajchowski, Darren W. Davis, Mary Tagliaferri, Ute Hoch, Edith A. Perez	17
5	Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial 2017 ·Breast Cancer Research and Treatment ·Javier Cortés, Hope S. Rugo, Ahmad Awada, Chris Twelves, Edith A. Perez, Seock‐Ah Im, (unknown), Lee S. Schwartzberg, Véronique Dièras, Denise A. Yardley, David A. Potter, Audrey Mailliez, Alvaro Moreno‐Aspitia, Jin-Seok Ahn, Carol Zhao, Ute Hoch, Mary Tagliaferri, Alison L. Hannah, Joyce O’Shaughnessy	36
6	PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies 2017 ·Annals of Oncology ·Adi Diab, Michael E. Hurwitz, Nizar M. Tannir, Chantale Bernatchez, Cara Haymaker, Salah-Eddine Bentebibel, Brendan D. Curti, Michael K. Wong, I. Gergel, Mary Tagliaferri, Jonathan Zalevsky, Ute Hoch, Sandra Aung, Michael J. Imperiale, (unknown), Scott S. Tykodi, Igor Puzanov, Harriet M. Kluger, Patrick Hwu, Mario Sznol	4
7	Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy 2017 ·PLoS ONE ·Deborah H. Charych, (unknown), Vidula Dixit, Peter Kirk, Thomas K. H. Chang, John L. Langowski, Werner Rubas, Stephen K. Doberstein, Michael A. Eldon, Ute Hoch, Jonathan Zalevsky	111
8	Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer 2017 ·Cancer Chemotherapy and Pharmacology ·Heinz‐Josef Lenz, Philip Philip, Mark Saunders, Tatjana Kolevska, (unknown), Leslie Samuel, Shailesh Bondarde, (unknown), Mary Tagliaferri, Ute Hoch, Alison L. Hannah, (unknown)	7
9	Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial 2016 ·SpringerPlus ·Javier Cortés, Hope S. Rugo, Chris Twelves, Ahmad Awada, Edith A. Perez, Seock‐Ah Im, Carol Zhao, Ute Hoch, (unknown), James Buchanan, Mary Tagliaferri, Alison L. Hannah, Joyce O’Shaughnessy	4
10	Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial 2015 ·The Lancet Oncology ·Edith A. Perez, Ahmad Awada, Joyce O’Shaughnessy, Hope S. Rugo, Chris Twelves, Seock‐Ah Im, (unknown), Lee S. Schwartzberg, Véronique Dièras, Denise A. Yardley, David A. Potter, Audrey Mailliez, Alvaro Moreno‐Aspitia, Jin-Seok Ahn, Carol Zhao, Ute Hoch, Mary Tagliaferri, Alison L. Hannah, Javier Cortés	62
11	NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer 2015 ·BMC Cancer ·Chris E. Adkins, Mohamed Ismail Nounou, (unknown), Afroz S. Mohammad, Tori B. Terrell-Hall, (unknown), Michael A. Eldon, Ute Hoch, Paul R. Lockman	38
12	Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models 2014 ·Cancer Chemotherapy and Pharmacology ·Ute Hoch, (unknown), Randall K. Johnson, Michael A. Eldon	45
13	Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study 2013 ·The Lancet Oncology ·Ahmad Awada, Agustin A. García, Stephen L. Chan, Guy Jérusalem, Robert E. Coleman, Manon Huizing, (unknown), (unknown), John Hamm, Peter Barrett‐Lee, Véronique Cocquyt, Kostandinos Sideras, David Young, Carol Zhao, Yen Lin Chia, Ute Hoch, Alison L. Hannah, Edith A. Perez	49
14	Phase II Multicenter Trial of Voreloxin as Second-Line Therapy in Chemotherapy-Sensitive or Refractory Small Cell Lung Cancer 2011 ·Journal of Thoracic Oncology ·Lee M. Krug, Jeffrey Crawford, David S. Ettinger, Geoffrey I. Shapiro, David R. Spigel, Tony Reiman, Jennifer S. Temel, Glenn Michelson, Donald Y. Young, Ute Hoch, Daniel C. Adelman	18
15	SNS-032, a novel inhibitor of cyclin-dependent kinases 2, 7 and 9, blocks transcription of cyclin D1 and Mcl-1, causing cell death in mantle cell lymphoma cell lines 2008 ·Cancer Research ·Rong Chen, Sherri Chubb, Ute Hoch, (unknown), Judith A. Fox, Varsha Gandhi, William Plunkett	1
16	Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models 2008 ·Cancer Chemotherapy and Pharmacology ·Ute Hoch, Jennifer Lynch, Yuji Sato, Shigeki Kashimoto, (unknown), Yasuji Furutani, Jeffrey A. Silverman	52
17	A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties 2008 ·Bioorganic & Medicinal Chemistry Letters ·Ingrid Choong, Iana M. Serafimova, (unknown), David E. Stockett, (unknown), Sravanthi Cheeti, (unknown), Bruce J. Fahr, (unknown), Michelle R. Arkin, Duncan Walker, Ute Hoch	10
18	SNS-595 potentiates the in vivo antitumor activity of carboplatin, cisplatin, and gemcitabine in solid tumor xenografts. 2007 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Jeffrey J. Jones, (unknown), Ute Hoch, Jeffrey A. Silverman, Anthony R. Howlett, Caroline D. Scatena	3
19	Molecular basis for the w-regiospecificity of the CYP4A2 and CYP4A3 fatty acid hydroxylases 2000 ·Journal of Biological Chemistry ·Ute Hoch	25
20	Structural Determination of the Substrate Specificities and Regioselectivities of the Rat and Human Fatty Acid ω-Hydroxylases 2000 ·Archives of Biochemistry and Biophysics ·Ute Hoch, Zhoupeng Zhang, Deanna L. Kroetz, Paul R. Ortiz de Montellano	77

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact